Published in Blood on January 22, 2004
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | NCT00137995
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol (2010) 5.20
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2009) 2.06
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol (2012) 1.66
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma (2008) 1.61
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am (2008) 1.21
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica (2008) 1.16
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol (2010) 1.11
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T (2010) 1.03
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma (2010) 1.02
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res (2013) 1.01
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer (2013) 1.00
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project. Haematologica (2012) 0.93
AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy. Adv Hematol (2012) 0.89
Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol (2014) 0.88
Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics (2008) 0.87
The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma. Adv Hematol (2012) 0.86
Current clinical indications for plerixafor. Transfus Med Hemother (2013) 0.86
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2014) 0.84
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia (2015) 0.82
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer (2005) 0.82
Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer (2014) 0.81
Radiofrequency ablation of lymphoma. Blood (2005) 0.81
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol (2015) 0.80
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. Chin J Cancer (2015) 0.80
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica (2013) 0.80
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol (2014) 0.80
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer (2012) 0.80
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol (2013) 0.79
Treatment of diffuse large B cell lymphoma. Korean J Intern Med (2012) 0.78
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2014) 0.78
Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. Clinicoecon Outcomes Res (2010) 0.78
Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings. Medicine (Baltimore) (2016) 0.77
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. Chin Med J (Engl) (2015) 0.77
A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. Sultan Qaboos Univ Med J (2015) 0.75
Autologous stem cell transplantation for aggressive lymphomas. Mediterr J Hematol Infect Dis (2012) 0.75
Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol (2016) 0.75
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma. Cancer Chemother Pharmacol (2016) 0.75
Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas. Oncol Lett (2010) 0.75
High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. Ger Med Sci (2007) 0.75
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol (2016) 0.75
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol (2008) 0.75
A Review of Autologous Stem Cell Transplantation in Lymphoma. Curr Hematol Malig Rep (2017) 0.75
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol (2010) 5.20
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol (2004) 3.42
How I treat extramedullary acute myeloid leukemia. Blood (2011) 3.42
Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med (2007) 3.39
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Analyzing Recurrent Event Data With Informative Censoring. J Am Stat Assoc (2001) 2.93
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood (2011) 2.68
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol (2006) 2.51
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 2.33
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 2.31
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol (2011) 2.24
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer (2006) 2.09
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc Natl Acad Sci U S A (2007) 2.02
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol (2012) 1.99
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98
Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models. J Am Stat Assoc (2009) 1.95
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res (2007) 1.94
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One (2009) 1.93
Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol (2002) 1.88
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood (2006) 1.88
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res (2005) 1.86
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
A tumour suppressor network relying on the polyamine-hypusine axis. Nature (2012) 1.85
Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell (2009) 1.84
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol (2009) 1.84
The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood (2002) 1.84
The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell (2006) 1.83
Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol (2004) 1.80